Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA
Jagsi R, Griffith K, Harris E, Wright J, Recht A, Taghian A, Lee L, Moran M, Small W, Johnstone C, Rahimi A, Freedman G, Muzaffar M, Haffty B, Horst K, Powell S, Sharp J, Sabel M, Schott A, El-Tamer M. Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA. Journal Of Clinical Oncology 2023, 42: 390-398. PMID: 38060195, DOI: 10.1200/jco.23.02270.Peer-Reviewed Original ResearchBreast-conserving surgeryIpsilateral breast eventsEndocrine therapyPostmenopausal patientsBreast cancerCrude rateLower riskBreast cancer-specific survival ratesUnifocal invasive breast cancersYears of ETCancer-specific survival ratesStage I breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Omission of radiotherapyYounger postmenopausal patientsPatients age 50Primary end pointBreast conserving surgeryGrowth factor receptor 2I breast cancerInvasive breast cancerRecurrence 5 yearsPatients age 65Single-arm trial